Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-06-11

FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Synjardy (empagliflozin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharmaceuticals, updating the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SYNJARDY (empagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for SYNJARDY (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)